{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T20:09:31Z","timestamp":1785096571827,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP13748"],"award-info":[{"award-number":["MOP13748"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s12012-018-9468-9","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T07:56:31Z","timestamp":1530086191000},"page":"557-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5082-3836","authenticated-orcid":false,"given":"Brian B.","family":"Hasinoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daywin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"9468_CR1","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., et al. (2010). Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Research, 70, 1970\u20131980.","journal-title":"Cancer Research"},{"key":"9468_CR2","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., et al. (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383\u20136391.","journal-title":"Cancer Research"},{"key":"9468_CR3","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1021\/jm801329v","volume":"52","author":"HJ Zhou","year":"2009","unstructured":"Zhou, H. J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., et al. (2009). Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). Journal of Medicinal Chemistry, 52, 3028\u20133038.","journal-title":"Journal of Medicinal Chemistry"},{"key":"9468_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10900","author":"EM Huber","year":"2016","unstructured":"Huber, E. M., Heinemeyer, W., Li, X., Arendt, C. S., Hochstrasser, M., & Groll, M. (2016). A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome. Nature Communications. \n                    https:\/\/doi.org\/10.1038\/ncomms10900\n                    \n                  .","journal-title":"Nature Communications"},{"key":"9468_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","volume":"14","author":"M Groll","year":"2006","unstructured":"Groll, M., Berkers, C. R., Ploegh, H. L., & Ovaa, H. (2006). Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure, 14, 451\u2013456.","journal-title":"Structure"},{"key":"9468_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","volume":"828","author":"M Gavazzoni","year":"2018","unstructured":"Gavazzoni, M., Vizzardi, E., Gorga, E., Bonadei, I., Rossi, L., Belotti, A., et al. (2018). Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. European Journal of Pharmacology, 828, 80\u201388.","journal-title":"European Journal of Pharmacology"},{"key":"9468_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11936-018-0618-y","volume":"20","author":"DH Lee","year":"2018","unstructured":"Lee, D. H., & Fradley, M. G. (2018). Cardiovascular complications of multiple myeloma treatment: Evaluation, management, and prevention. Current Treatment Options in Cardiovascular Medicine, 20, 19.","journal-title":"Current Treatment Options in Cardiovascular Medicine"},{"key":"9468_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","volume":"3","author":"W Li","year":"2017","unstructured":"Li, W., Garcia, D., Cornell, R. F., Gailani, D., Laubach, J., Maglio, M. E., et al. (2017). Cardiovascular and thrombotic complications of novel multiple myeloma therapies: A review. JAMA Oncology, 3, 980\u2013988.","journal-title":"JAMA Oncology"},{"key":"9468_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.hfc.2016.12.001","volume":"13","author":"G Koulaouzidis","year":"2017","unstructured":"Koulaouzidis, G., & Lyon, A. R. (2017). Proteasome inhibitors as a potential cause of heart failure. Heart Failure Clinics, 13, 289\u2013295.","journal-title":"Heart Failure Clinics"},{"key":"9468_CR10","first-page":"167","volume":"16","author":"D Schlafer","year":"2017","unstructured":"Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2017). Safety of proteasome inhibitors for treatment of multiple myeloma. Expert Opinion on Drug Safety, 16, 167\u2013183.","journal-title":"Expert Opinion on Drug Safety"},{"key":"9468_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","volume":"26","author":"DC Cole","year":"2018","unstructured":"Cole, D. C., & Frishman, W. H. (2018). Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiology in Review, 26, 122\u2013129.","journal-title":"Cardiology in Review"},{"key":"9468_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","volume":"21","author":"EW Grandin","year":"2015","unstructured":"Grandin, E. W., Ky, B., Cornell, R. F., Carver, J., & Lenihan, D. J. (2015). Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. Journal of Cardiac Failure, 21, 138\u2013144.","journal-title":"Journal of Cardiac Failure"},{"key":"9468_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hajek, R., et al. (2016). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study. Lancet Oncology, 17, 27\u201338.","journal-title":"Lancet Oncology"},{"key":"9468_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/bjh.14708","volume":"178","author":"JP Laubach","year":"2017","unstructured":"Laubach, J. P., Moslehi, J. J., Francis, S. A., San Miguel, J. F., Sonneveld, P., Orlowski, R. Z., et al. (2017). A retrospective analysis of 3954 patients in phase 2\/3 trials of bortezomib for the treatment of multiple myeloma: Towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology, 178, 547\u2013560.","journal-title":"British Journal of Haematology"},{"key":"9468_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., et al. (2016). Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine, 374, 1621\u20131634.","journal-title":"New England Journal of Medicine"},{"key":"9468_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","volume":"130","author":"V Sanchorawala","year":"2017","unstructured":"Sanchorawala, V., Palladini, G., Kukreti, V., Zonder, J. A., Cohen, A. D., Seldin, D. C., et al. (2017). A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 130, 597\u2013605.","journal-title":"Blood"},{"key":"9468_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/14740338.2017.1344212","volume":"16","author":"A Bonnet","year":"2017","unstructured":"Bonnet, A., & Moreau, P. (2017). Safety of ixazomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 16, 973\u2013980.","journal-title":"Expert Opinion on Drug Safety"},{"key":"9468_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24608","volume":"92","author":"H Jouni","year":"2017","unstructured":"Jouni, H., Aubry, M. C., Lacy, M. Q., Vincent Rajkumar, S., Kumar, S. K., Frye, R. L., et al. (2017). Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. American Journal of Hematology, 92, 220\u2013221.","journal-title":"American Journal of Hematology"},{"key":"9468_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","volume":"17","author":"BB Hasinoff","year":"2017","unstructured":"Hasinoff, B. B., Patel, D., & Wu, X. (2017). Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib. Cardiovascular Toxicology, 17, 237\u2013250.","journal-title":"Cardiovascular Toxicology"},{"key":"9468_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/9781118084410","volume-title":"Kinetics of enzyme action: Essential principles for drug hunters","author":"RL Stein","year":"2011","unstructured":"Stein, R. L. (2011). Kinetics of enzyme action: Essential principles for drug hunters. Hoboken, NJ: Wiley."},{"key":"9468_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/9781118540398","volume-title":"Evaluation of enzyme inhibitors in drug discovery: A guide for medicinal chemists and pharmacologists","author":"RA Copeland","year":"2013","unstructured":"Copeland, R. A. (2013). Evaluation of enzyme inhibitors in drug discovery: A guide for medicinal chemists and pharmacologists. Hoboken, NJ: Wiley."},{"key":"9468_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.abb.2017.12.020","volume":"639","author":"BB Hasinoff","year":"2018","unstructured":"Hasinoff, B. B. (2018). Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome. Archives of Biochemistry and Biophysics, 639, 52\u201358.","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"9468_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12012-012-9183-x","volume":"13","author":"BB Hasinoff","year":"2013","unstructured":"Hasinoff, B. B., Patel, D., & Wu, X. (2013). The dual-targeted HER1\/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin. Cardiovascular Toxicology, 13, 33\u201347.","journal-title":"Cardiovascular Toxicology"},{"key":"9468_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.228650","volume":"356","author":"BB Hasinoff","year":"2016","unstructured":"Hasinoff, B. B., Wu, X., Patel, D., Kanagasabai, R., Karmahapatra, S., & Yalowich, J. C. (2016). Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase II\u03b1 isoform. Journal of Pharmacology and Experimental Therapeutics, 356, 397\u2013409.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"9468_CR25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1006\/jmcc.1996.0163","volume":"28","author":"F Li","year":"1996","unstructured":"Li, F., Wang, X., Capasso, J. M., & Gerdes, A. M. (1996). Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. Journal of Molecular and Cellular Cardiology, 28, 1737\u20131746.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9468_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bcp.2014.12.008","volume":"93","author":"BB Hasinoff","year":"2015","unstructured":"Hasinoff, B. B., Wu, X., Yadav, A. A., Patel, D., Zhang, H., Wang, D.-S., et al. (2015). Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochemical Pharmacology, 93, 266\u2013276.","journal-title":"Biochemical Pharmacology"},{"key":"9468_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.abb.2017.09.003","volume":"633","author":"BB Hasinoff","year":"2017","unstructured":"Hasinoff, B. B., & Patel, D. (2017). Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity. Archives of Biochemistry and Biophysics, 633, 23\u201328.","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"9468_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cbi.2013.04.016","volume":"204","author":"R Xiong","year":"2013","unstructured":"Xiong, R., Siegel, D., & Ross, D. (2013). The activation sequence of cellular protein handling systems after proteasomal inhibition in dopaminergic cells. Chemico-Biological Interactions, 204, 116\u2013124.","journal-title":"Chemico-Biological Interactions"},{"key":"9468_CR29","first-page":"158","volume-title":"Razoxane and dexrazoxane\u2014Two multifunctional agents","author":"BB Hasinoff","year":"2010","unstructured":"Hasinoff, B. B. (2010). The pharmacology of dexrazoxane: Iron chelating prodrug and topoisomerase II inhibitor. In K. Hellmann & W. Rhomberg (Eds.), Razoxane and dexrazoxane\u2014Two multifunctional agents (pp.\u00a0158\u2013167). Dordrecht: Springer."},{"key":"9468_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ppedcard.2014.09.006","volume":"36","author":"E Herman","year":"2014","unstructured":"Herman, E., Hasinoff, B. B., Steiner, R., & Lipshultz, S. E. (2014). A review of the preclinical development of dexrazoxane. Progress in Pediatric Cardiology, 36, 33\u201338.","journal-title":"Progress in Pediatric Cardiology"},{"key":"9468_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12012-016-9386-7","volume":"17","author":"BB Hasinoff","year":"2017","unstructured":"Hasinoff, B. B., Patel, D., & Wu, X. (2017). The myocyte-damaging effects of the BCR-ABL1-targeted tyrosine kinase inhibitors increase with potency and decrease with specificity. Cardiovascular Toxicology, 17, 297\u2013306.","journal-title":"Cardiovascular Toxicology"},{"key":"9468_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/cvr\/cvn289","volume":"81","author":"MS Willis","year":"2009","unstructured":"Willis, M. S., Schisler, J. C., Portbury, A. L., & Patterson, C. (2009). Build it up-Tear it down: Protein quality control in the cardiac sarcomere. Cardiovascular Research, 81, 439\u2013448.","journal-title":"Cardiovascular Research"},{"key":"9468_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00990974","volume":"21","author":"RG Taylor","year":"1995","unstructured":"Taylor, R. G., Tassy, C., Briand, M., Robert, N., Briand, Y., & Ouali, A. (1995). Proteolytic activity of proteasome on myofibrillar structures. Molecular Biology Reports, 21, 71\u201373.","journal-title":"Molecular Biology Reports"},{"key":"9468_CR34","doi-asserted-by":"publisher","first-page":"9929","DOI":"10.1074\/jbc.R110.170571","volume":"286","author":"AL Portbury","year":"2011","unstructured":"Portbury, A. L., Willis, M. S., & Patterson, C. (2011). Tearin\u2019 up my heart: Proteolysis in the cardiac sarcomere. Journal of Biological Chemistry, 286, 9929\u20139934.","journal-title":"Journal of Biological Chemistry"},{"key":"9468_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s004410051315","volume":"296","author":"DM Eble","year":"1999","unstructured":"Eble, D. M., Spragia, M. L., Ferguson, A. G., & Samarel, A. M. (1999). Sarcomeric myosin heavy chain is degraded by the proteasome. Cell and Tissue Research, 296, 541\u2013548.","journal-title":"Cell and Tissue Research"},{"key":"9468_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","volume":"67","author":"DE Reece","year":"2011","unstructured":"Reece, D. E., Sullivan, D., Lonial, S., Mohrbacher, A. F., Chatta, G., Shustik, C., et al. (2011). Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology, 67, 57\u201367.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9468_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/17425255.2018.1417388","volume":"14","author":"M Salvini","year":"2018","unstructured":"Salvini, M., Troia, R., Giudice, D., Pautasso, C., Boccadoro, M., & Larocca, A. (2018). Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism and Toxicology, 14, 91\u201399.","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"key":"9468_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","volume":"49","author":"E Gallerani","year":"2013","unstructured":"Gallerani, E., Zucchetti, M., Brunelli, D., Marangon, E., Noberasco, C., Hess, D., et al. (2013). A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. European Journal of Cancer, 49, 290\u2013296.","journal-title":"European Journal of Cancer"},{"key":"9468_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/dmd.112.047662","volume":"41","author":"Z Wang","year":"2013","unstructured":"Wang, Z., Yang, J., Kirk, C., Fang, Y., Alsina, M., Badros, A., et al. (2013). Clinical pharmacokinetics, metabolism, and drug\u2013drug interaction of carfilzomib. Drug Metabolism and Disposition, 41, 230\u2013237.","journal-title":"Drug Metabolism and Disposition"},{"key":"9468_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10637-016-0327-x","volume":"34","author":"JR Infante","year":"2016","unstructured":"Infante, J. R., Mendelson, D. S., Burris III, H. A., Bendell, J. C., Tolcher, A. W., Gordon, M. S., et al. (2016). A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Investigational New Drugs, 34, 216\u2013224.","journal-title":"Investigational New Drugs"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-018-9468-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T04:42:58Z","timestamp":1569127378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-018-9468-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9468"],"URL":"https:\/\/doi.org\/10.1007\/s12012-018-9468-9","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"27 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}